Protagonist Therapeutics Strategy and Business Model

Executive Overview

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on peptide-based medicines. Founded in 2006 and headquartered in Newark, California, the company uses a proprietary peptide discovery and engineering platform to design both injectable and oral drug candidates. As of 2024, its strategic center of gravity was two programs: rusfertide, a hepcidin mimetic being developed for polycythemia vera, and JNJ-77242113, formerly PN-235, an oral interleukin-23 (IL-23) receptor antagonist partnered with Johnson & Johnson for immune-mediated diseases. Protagonist’s strategy is not to build a broad, fully integrated pharmaceutical company all at once. Instead, it aims to create differentiated peptide assets, keep selected economics where it has conviction, and partner with larger drug companies when global development or commercialization scale matters. Its owned operating footprint is relatively concentrated in the United States, but its development and eventual commercial reach is global through partners such as Takeda and Johnson & Johnson. Because Protagonist had no approved products as of 2024, reported revenue of #N/A reflects collaboration, milestone, and licensing activity rather than recurring product sales.

Protagonist Therapeutics at a Glance

Logo
Common name	Protagonist Therapeutics
Full legal name	Protagonist Therapeutics, Inc.
Headquarters	Newark, California, United States
Ownership	Public company
Ticker	PTGX
Exchange	NASDAQ
Market Cap	$7.65B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2006; initial public offering in 2016; Janssen collaboration on oral IL-23 receptor antagonists in 2017; rusfertide clinical hold resolved in 2023; Takeda rusfertide collaboration announced in 2024; amended Johnson & Johnson/Janssen IL-23 collaboration announced in 2024.
Industry or industries	Biotechnology, biopharmaceuticals, peptide therapeutics, hematology, immunology
Key products or services	Clinical-stage peptide drug discovery and development; rusfertide; partnered oral IL-23 receptor antagonist program JNJ-77242113; peptide platform licensing and collaboration economics
Geographic footprint	U.S.-based operations with global development and future commercialization reach through pharmaceutical partners
Business segments as officially reported	One operating and reportable segment
Company website	https://www.protagonist-inc.com/

1. What Is the Strategy of Protagonist Therapeutics?

Public disclosures through 2024 point to a coherent strategy: build differentiated peptide medicines, focus internal resources on the highest-value programs, and use partnerships to add capital, scale, and commercial reach where that is more efficient than building a large infrastructure alone. The company’s strategy is best understood through the Playing to Win framework.

1a. What is the winning aspiration of Protagonist Therapeutics?

Protagonist’s winning aspiration is to become a leading peptide therapeutics company by translating its platform into clinically and commercially meaningful medicines. In practice, as of 2024, “winning” meant three things: first, turning rusfertide into a registrational and potentially commercial asset in hematology; second, converting the oral IL-23 program into a major partnered franchise; and third, proving that its peptide platform can repeatedly generate valuable molecules, not just one-off programs. Protagonist has not publicly framed its strategy around a mature-pharma style revenue target. Its more tangible markers of success have been clinical milestones, partnership economics, and retaining optionality over future pipeline value.
1b. Where does Protagonist Therapeutics play?

Protagonist plays in specialty indications where peptide therapeutics may offer a meaningful edge over existing treatment formats. Its most important arenas as of 2024 were hematology, especially polycythemia vera, and IL-23-mediated inflammatory diseases such as psoriasis and potentially other immune disorders through its Johnson & Johnson collaboration. The company does not try to compete across broad primary-care drug categories. It also chooses to play through a hybrid model: it advances some assets deeply enough to capture substantial value, but it partners selectively when development breadth, global commercialization, or capital intensity favor a large-pharma partner.
1c. How does Protagonist Therapeutics plan to win?

Protagonist’s “how to win” is based on modality-level differentiation and disciplined partnering. The company focuses on peptide drugs that can combine high target specificity with dosing or delivery advantages that may be difficult for traditional small molecules or antibodies to match. Rusfertide is an example of a mechanistically targeted hematology asset with a clear disease rationale. The IL-23 program shows another angle: using oral peptide technology to pursue a target class otherwise dominated by injectable biologics. Protagonist then tries to match asset ownership to strategic fit. Where it can create disproportionate value by staying close to the asset, it does so. Where global scale, large trials, or commercial muscle are more important, it partners.
1d. What capabilities must Protagonist Therapeutics have in place?

The critical capabilities are highly specific. Protagonist needs strong peptide design and medicinal chemistry, translational biology, formulation know-how, chemistry, manufacturing, and controls (CMC), clinical development execution, regulatory judgment, and alliance management. Intellectual property also matters because peptide-based franchises can be vulnerable if composition, formulation, or use claims are weak. For a company of Protagonist’s size, another essential capability is prioritization: choosing which programs deserve direct investment and which are better advanced with a partner.
1e. What management systems does Protagonist Therapeutics require?

To execute this strategy, Protagonist needs strong portfolio governance, stage-gated R&D decision-making, rigorous quality and regulatory systems, and tight cash planning. It also needs formal alliance-governance mechanisms with partners such as Takeda and Johnson & Johnson, because major value creation depends on joint decisions, milestone timing, and division of responsibilities. For investors, the company’s management system also has to support clear communication around trial design, regulatory progress, and the difference between one-time collaboration revenue and enduring asset value.

2. What Are the Current Strategic Initiatives of Protagonist Therapeutics?

Advance rusfertide through late-stage development: Protagonist’s most important internally anchored initiative in 2024 was moving rusfertide forward in polycythemia vera after earlier regulatory issues were resolved. That includes pivotal-study execution, regulatory preparation, and the CMC work needed to support a potential filing and launch path.
Execute the Takeda collaboration for rusfertide: In 2024, Protagonist announced a collaboration with Takeda around rusfertide. That turned alliance execution into a strategic initiative in its own right. Development governance, manufacturing scale-up, role clarity, and commercialization planning became as important as the underlying clinical data.
Expand the value of the oral IL-23 franchise: In April 2024, Protagonist and Janssen amended and restated their collaboration around JNJ-77242113 and related oral IL-23 receptor antagonists. The strategic aim is to help broaden the development program while converting Protagonist’s platform innovation into milestone, royalty, and long-duration franchise value.
Maintain peptide platform productivity: Management has continued to position Protagonist as more than a two-asset company. Even with heightened investor focus on rusfertide and the IL-23 program, platform productivity remains a strategic priority because it underpins future partnering leverage and valuation durability.
Preserve financing flexibility: A major strategic initiative in 2024 was turning collaboration economics into balance-sheet strength. For a clinical-stage biotech, reducing reliance on frequent equity raises is not just a finance choice; it is a strategic enabler that gives management more control over timing and portfolio decisions.

3. What Is the Business Model of Protagonist Therapeutics?

What customers actually buy

As of 2024, Protagonist did not primarily sell approved medicines. Its economic customers bought access to assets and rights: drug candidates, development data, intellectual property, and the option to commercialize programs globally. In other words, the company’s current business model is based more on creating and monetizing high-value molecules than on shipping commercial product volume.

Revenue model

The revenue model is collaboration- and licensing-based. That typically includes upfront payments, option fees, milestone payments, and potentially royalties or profit-sharing arrangements if partnered products reach the market. This is very different from a subscription, rental, or pure pay-per-use model. It is asset-based pharmaceutical economics, with revenue tied to scientific progress and contract structure.

Recurring versus one-time economics

Today, the business appears more lumpy than recurring. Upfronts and milestones can create large reported revenue in one period and much lower revenue in another. Over time, if partnered products are approved, the model could become more repeat-driven through royalties, commercial milestones, or shared profits. Until then, Protagonist’s economics are more episodic than those of a mature biopharma company with established product sales.

Pricing power

Protagonist’s pricing power today shows up mainly in business development negotiations. The stronger the clinical data and the clearer the differentiation, the better the company’s deal terms can be. At the future product level, pricing power would depend on whether its assets deliver compelling medical and convenience benefits, such as reducing the need for phlebotomy in polycythemia vera or offering an oral alternative in immune-mediated disease categories dominated by injectables.

Why the business mix matters

The mix between owned and partnered assets is central to Protagonist’s economics. A heavily partnered asset can be capital-light and strategically de-risked, but it also cedes a large share of downstream revenue. A more retained asset offers higher upside but requires more investment and creates more operational burden. Protagonist’s model tries to balance these tradeoffs rather than choosing only one path.

What drives margin and cash generation

Gross margin is not yet the most useful lens because the company had no broad product-sales base as of 2024. Operating performance is driven mainly by R&D spending, clinical-trial costs, manufacturing readiness, and general corporate overhead. Cash generation is heavily influenced by collaboration timing. That means a strong year for cash inflow may come from deal execution rather than from underlying recurring demand, while a heavy investment year may reflect pipeline advancement rather than commercial weakness.

4. What Products and/or Services Does Protagonist Therapeutics Sell?

Strictly speaking, as of 2024 Protagonist did not sell approved commercial drugs. Its most important economic offerings were its clinical-stage drug candidates and the rights associated with them.

Rusfertide: Rusfertide is a hepcidin mimetic candidate being developed for polycythemia vera. Strategically, this has been Protagonist’s most important internally anchored hematology asset because it is relatively advanced, addresses a defined specialist market, and could support meaningful value creation if successfully commercialized.
JNJ-77242113, formerly PN-235: This oral IL-23 receptor antagonist is partnered with Johnson & Johnson. It is important not because Protagonist will necessarily book the end-market product sales directly, but because the program validates the company’s peptide platform and can generate substantial collaboration economics if development succeeds.
Peptide discovery platform and associated intellectual property: Protagonist’s broader offering to potential partners is its ability to discover and optimize peptide therapeutics against attractive targets. It does not operate like a fee-for-service contract research company; rather, it creates proprietary assets that can later be licensed or co-developed.

In revenue and strategic terms, rusfertide and the IL-23 program have been the company’s dominant assets. Earlier-stage discovery programs matter, but mainly as option value and proof that the platform can produce additional candidates.

5. What Are the Key Competitors or Peers of Protagonist Therapeutics?

For Protagonist, competition is better understood by program and therapeutic area than by simple corporate peer grouping. The company has no single like-for-like rival with the same portfolio shape. Its competitive set spans both hematology and immunology.

Incyte: Incyte’s Jakafi is an established therapy in polycythemia vera and remains a key point of comparison in specialist hematology.
PharmaEssentia: PharmaEssentia markets Besremi for polycythemia vera and competes for the same physician attention and treatment algorithm position.
Bristol Myers Squibb: Through Sotyktu, Bristol Myers provides an important commercial benchmark for oral immunology therapies in psoriasis.
AbbVie: AbbVie’s Skyrizi is a major IL-23 biologic franchise in psoriasis and inflammatory bowel disease, making it a relevant competitor at the market level.
Johnson & Johnson: Johnson & Johnson’s Tremfya competes in IL-23-driven markets, even though Johnson & Johnson is also Protagonist’s partner on JNJ-77242113. In other words, it is collaborator and market comparator at the same time.
Eli Lilly: Eli Lilly’s immunology portfolio, including psoriasis and inflammatory bowel disease products, competes for the same prescriber and payer budgets.
Novartis: Novartis is a major psoriasis competitor through Cosentyx and remains relevant as a substitute therapy benchmark even though the mechanism differs.
UCB: UCB’s Bimzelx is another strong psoriasis competitor and contributes to the crowded specialty-dermatology landscape any future oral therapy must enter.

The key point is that Protagonist’s competitive context is asset-specific. Rusfertide competes in hematology treatment pathways. The oral IL-23 program competes against large global immunology franchises, many of them injectable biologics with strong physician familiarity and payer relationships.

6. What Is the Marketing Strategy of Protagonist Therapeutics?

As of 2024, Protagonist’s marketing strategy was not built around consumer advertising or a large commercial field force. For a clinical-stage biotech, marketing is primarily scientific, medical, and strategic. The company’s near-term “marketing” consists of communicating data clearly to regulators, investigators, key opinion leaders, investors, and potential partners.

That means congress presentations, peer-reviewed publications, investor materials, and disciplined external messaging matter more than brand advertising. In specialist categories such as hematology and immunology, scientific credibility is often the most important pre-launch marketing asset. Protagonist’s data narrative around rusfertide and the oral IL-23 program is therefore central to how it builds interest and negotiating leverage.

For partnered assets, eventual commercial marketing would sit largely with the larger partner. If rusfertide reaches market under a shared or partnered structure, marketing would likely focus on hematologist education, treatment-pathway positioning, patient identification, and payer access. For the IL-23 program, broad-scale dermatology and gastroenterology marketing would be expected to rely on Johnson & Johnson’s existing immunology infrastructure. In short, marketing is a supporting capability for Protagonist today, while scientific differentiation remains the main driver of value.

7. What Are the Key Customer Segments of Protagonist Therapeutics?

Protagonist’s customer base needs to be split into current economic customers and future clinical end markets.

Current economic customers: The most important customers today are large pharmaceutical collaborators and licensees, especially counterparties such as Johnson & Johnson and Takeda. This means current revenue is concentrated in a very small number of sophisticated buyers.
Hematology prescribers and treatment centers: If rusfertide is commercialized, the core end market would likely be hematologists and centers treating polycythemia vera and related blood disorders. This is a focused specialist market, not mass primary care.
Dermatology and gastroenterology specialists: For the IL-23 program, the relevant end-market users are specialist prescribers in immune-mediated disease categories, depending on the indications ultimately pursued and approved.
Payers and health systems: Specialty-drug adoption depends heavily on reimbursement, formulary positioning, and evidence of clinical and economic value. Even when Protagonist is not the direct seller, payers remain a crucial customer group at the ecosystem level.
Patients and patient advocates: In rare and specialty diseases, patient experience and treatment burden can materially affect uptake. This matters especially where a drug may change the practical treatment pathway, not just a laboratory marker.

So the company is currently concentrated in a few collaboration counterparties, but its future clinical markets would be broader and specialist-led.

8. What Is the Sales Model of Protagonist Therapeutics?

Today, Protagonist’s sales model is mostly a business development model rather than a product-distribution model. It sells value through negotiated licensing and collaboration agreements. Those deals are long-cycle, high-value, and relationship-driven, involving scientific diligence, intellectual-property review, and complex economic structures.

If its programs reach commercialization, the sales model would shift to specialty pharma channels. Rusfertide would likely require a focused commercial approach aimed at hematologists and myeloproliferative-disease specialists, with strong market-access support and medical affairs. The IL-23 program, by contrast, would be expected to move through Johnson & Johnson’s larger specialty-selling infrastructure if approved.

This channel structure matters. Protagonist does not need a mass retail footprint or consumer distribution network. Instead, growth depends on a small number of strategic counterparties today and specialist prescriber networks tomorrow. That tends to increase the importance of launch planning, payer strategy, key opinion leader mapping, and alliance governance relative to broad inside-sales or e-commerce capabilities.

9. In What Geographies Does Protagonist Therapeutics Operate?

Protagonist’s owned operating footprint is relatively concentrated. Its headquarters are in Newark, California, and the company’s core research, management, and development operations have historically been U.S.-based. It is not organized like a large multinational pharmaceutical company with a dense network of country subsidiaries and manufacturing plants.

Its economic and development reach, however, is much broader than its physical footprint. Through multinational clinical studies, contract research organizations, contract manufacturers, and large pharmaceutical partners, Protagonist’s programs can be developed and eventually commercialized globally. That is especially true for assets partnered with Johnson & Johnson and Takeda.

So geographically, Protagonist is best described as a U.S.-centered biotech with global asset reach through partnerships rather than a globally distributed operator in its own right.

10. Who Are the Owners of Protagonist Therapeutics?

Protagonist Therapeutics is a publicly traded company listed under the ticker PTGX. As of its 2024 public disclosures, the company did not identify a controlling shareholder. Ownership appears to be primarily institutional, alongside insider holdings by management and directors. For practical purposes, this means governance is driven by a typical public-company mix of board oversight, institutional investor expectations, and management execution rather than by a single family, private equity sponsor, or state owner.

11. How Is Protagonist Therapeutics Organized?

For SEC reporting purposes, Protagonist has operated as one reportable segment. Practically, however, the company is organized around a small number of cross-functional priorities rather than around many autonomous divisions.

Platform research and discovery: peptide design, target selection, medicinal chemistry, and preclinical science
Development: clinical operations, clinical science, biometrics, medical, and regulatory affairs
CMC and technical operations: process development, manufacturing oversight, quality, and supply planning
Business development and alliance management: partnership negotiation, governance, and milestone execution
Corporate functions: finance, legal, investor relations, and administration

At a practical level, Protagonist is better understood as an asset-centric biotech than as a multi-brand or multi-division enterprise. Rusfertide and the IL-23 franchise are the main strategic poles around which the organization allocates attention and capital.

12. How Does Protagonist Therapeutics Operate?

Day to day, Protagonist operates as a focused drug developer. It starts with peptide design and target selection, advances candidates through preclinical testing, manages external manufacturing and toxicology work, runs or supports clinical trials, interacts with regulators, and manages partner relationships.

A large part of the operating model depends on externalization. Like many biotechs, Protagonist relies on contract research organizations and contract development and manufacturing organizations for substantial parts of trial execution and manufacturing. The company’s internal value creation comes from choosing the right targets, designing differentiated peptides, interpreting data well, protecting intellectual property, and making smart portfolio decisions.

The main operational complexities are typical of late-stage biotech but still material: patient enrollment, endpoint design, regulatory alignment, peptide manufacturing readiness, quality systems, and cross-company decision-making with partners. For Protagonist, value is created less by factory scale than by scientific judgment, disciplined program management, and the ability to translate molecule-level differentiation into approvable and commercially relevant products.

13. What Are the Growth Opportunities for Protagonist Therapeutics?

Rusfertide in polycythemia vera: The clearest growth opportunity is successful late-stage development and commercialization of rusfertide in polycythemia vera. Because this is a specialist market with a defined unmet need, success here could materially change Protagonist’s scale and economics.
Additional hepcidin-related or hematology indications: If the biology and clinical data support it, rusfertide or related science could extend into adjacent disorders. That is an external synthesis rather than a guaranteed outcome, but it is a logical platform adjacency.
Expansion of the oral IL-23 program: The Johnson & Johnson-partnered program has growth potential well beyond one indication if its efficacy, safety, and convenience profile hold up across larger development programs.
More platform deals: Protagonist can create growth without launching everything itself. Additional partnerships would validate the platform, diversify counterparty risk, and bring in capital to fund internal priorities.
Selective retention of economics: As the balance sheet strengthens, Protagonist may be able to retain more economics on future programs rather than licensing them too early. That would raise risk, but it could also increase long-term value capture.

The main constraints are clinical and regulatory risk, dependence on a small number of major counterparties, competitive intensity in both hematology and immunology, and the challenge of scaling peptide manufacturing and late-stage operations without losing capital discipline.

14. What Is the History of Protagonist Therapeutics?

Protagonist Therapeutics was founded in 2006 by a team led by Dinesh V. Patel to apply peptide science to drug discovery. In its early years, the company focused on building a peptide engineering platform capable of producing candidates that could address difficult biological targets and, in some cases, support oral delivery.

Protagonist became a public company in 2016, which gave it broader access to capital for platform development and clinical advancement. A major milestone came in 2017, when it entered into a collaboration with Janssen on oral IL-23 receptor antagonists, a deal that helped validate the platform externally.

Over time, the company became increasingly defined by two franchises: rusfertide in hematology and the partnered IL-23 program in immunology. Rusfertide’s path included a significant regulatory setback when the U.S. Food and Drug Administration placed the program on partial clinical hold in 2021; that hold was later lifted, reopening the path to pivotal development. In 2024, Protagonist announced a collaboration with Takeda for rusfertide and an amended collaboration with Janssen around the IL-23 franchise. Those 2024 moves marked an important evolution from a platform-centered biotech toward a company with two heavily validated strategic assets.

15. What Are the Key Assets of Protagonist Therapeutics?

Protagonist’s key assets are mostly intangible and program-specific rather than physical. That is typical for a clinical-stage biotech.

Rusfertide: This is one of the company’s most important value-bearing clinical assets because it sits close to potential commercial relevance.
The IL-23 collaboration franchise: The economic rights associated with JNJ-77242113 and related oral IL-23 receptor antagonists are strategic assets even though Protagonist is not the sole commercial owner.
Peptide discovery and engineering platform: The company’s core scientific know-how, design methods, and accumulated data are foundational assets because they can generate future candidates.
Intellectual property: Patents and know-how around compounds, formulations, and uses are essential to protecting future value.
Balance sheet strength created by collaboration economics: For a biotech, cash is a strategic asset because it determines how much optionality management has over timing, partnering, and internal investment.

Unlike a large pharmaceutical manufacturer, Protagonist’s competitive moat is not a massive production network. It is its science, its molecules, its contracts, and the capital to keep developing them.

16. What Is the Technology Strategy of Protagonist Therapeutics?

Protagonist’s technology strategy is fundamentally a molecule-design strategy. The company is not a software platform business; its technology edge lies in peptide engineering, formulation, and target engagement. It aims to create peptides that can achieve biologically attractive target specificity while overcoming some of the delivery and drug-like-property challenges that have historically limited peptide drugs.

Two parts of the technology strategy stand out. First, Protagonist uses its platform to go after targets where peptides may offer a better balance of selectivity and tractability than traditional small molecules. Second, it has emphasized the possibility of orally delivered peptide medicines in selected settings, which is strategically important in markets otherwise dominated by injectables.

Technology, in Protagonist’s case, is both an internal enabler and part of the commercial story. It helps the company discover assets, and it also gives partners a reason to work with Protagonist in the first place.

17. What Is the R&D Strategy of Protagonist Therapeutics?

Protagonist’s research and development strategy appears to favor validated biology, focused portfolios, and capital-efficient risk sharing. Rather than spreading resources across many unrelated discovery bets, the company has concentrated on programs where mechanism, disease rationale, and commercial relevance are easier to explain.

The R&D model also reflects a practical division of labor. Protagonist keeps the core peptide science and program insight close, while using partners, contract research organizations, and contract manufacturers to broaden execution capacity. For very large indications or global commercial opportunities, the company has shown willingness to partner rather than insist on full ownership.

A second important feature is translational discipline. In biotech, the best R&D strategy is often not simply finding more targets; it is designing studies, endpoints, and manufacturing packages that make clinical success legible to regulators, partners, physicians, and investors. Protagonist’s progression of rusfertide and the IL-23 program suggests that this translation from platform science to development-grade asset is central to its R&D philosophy.

18. What Is the Finance Strategy of Protagonist Therapeutics?

Finance strategy is unusually important for Protagonist because clinical-stage biotech value creation unfolds over long development cycles. The company’s approach has been to use collaboration economics to reduce dilution, extend cash runway, and preserve portfolio flexibility. In that sense, the finance strategy directly supports the corporate strategy.

As of 2024, Protagonist’s capital allocation priorities appeared to be late-stage development of rusfertide, continued platform investment, and maintaining enough liquidity to negotiate from strength rather than necessity. The company has also avoided prematurely building a full standalone commercial cost structure before product approval, which helps keep fixed overhead lower than at a fully integrated pharma company.

One important analytical point is that reported revenue and earnings can be noisy because milestone and collaboration accounting is lumpy. For Protagonist, investors typically need to look beyond one period’s revenue and focus on cash position, milestone structure, development obligations, and how much upside the company has retained in each major asset.

19. How Companies Like Protagonist Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Protagonist Therapeutics use Umbrex when they need high-caliber problem solving in strategy, operations, organization, marketing, sales, finance, technology, ERP, or AI, but do not need a full traditional consulting team with the related overhead. For a focused biotech with partnered assets and a small internal organization, that model can be especially useful.

Rusfertide launch strategy: Build a market-entry plan for polycythemia vera, including patient segmentation, treatment-pathway mapping, and likely adoption barriers.
Pricing and access planning: Develop evidence-based pricing scenarios, payer messaging, and reimbursement strategy for a specialty hematology therapy.
Alliance-governance design: Set up a clearer operating model, governance cadence, and decision-rights framework for large collaborations such as those with Takeda and Johnson & Johnson.
Portfolio prioritization: Create a capital-allocation model across rusfertide, partnered immunology assets, and earlier discovery programs to support board-level investment choices.
Indication expansion screening: Evaluate adjacent hematology or iron-regulation opportunities for rusfertide and rank them by clinical probability, market size, and strategic fit.
CMC and external manufacturing strategy: Assess peptide manufacturing scale-up options, vendor governance, cost structure, and late-stage supply risk.
Clinical development operating model improvement: Benchmark clinical operations, refine use of contract research organizations, and improve trial-management dashboards.
Medical affairs and key opinion leader strategy: Map the most influential hematology, dermatology, and gastroenterology stakeholders and design a scientific-engagement plan.
Business development support: Screen new peptide targets, partnership options, or in-licensing opportunities that fit Protagonist’s platform and capital constraints.
AI-enabled regulatory and knowledge workflows: Design practical uses of artificial intelligence for literature surveillance, regulatory-intelligence tracking, and internal knowledge management without trying to turn the company into a software enterprise.